p53R2 Antibody (A-5): sc-137174

p53R2 Antibody (A-5) is a mouse monoclonal IgG1 kappa light chain antibody, engineered to detect p53R2, also known as RRM2B, across mouse, rat, and human species. anti-p53R2 antibody (A-5) targets an epitope encompassing amino acids 52-351 at the C-terminus of human p53R2, ensuring precise binding for reliable detection in various assays such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). p53R2 is a critical regulatory subunit of ribonucleotide reductase, an essential enzyme responsible for the synthesis of deoxyribonucleotide triphosphates (dNTPs) required for DNA repair and replication. Structurally, p53R2 forms part of the ribonucleotide reductase complex, working in conjunction with the R1 subunit to control the production of dNTPs, particularly during the S-phase of the cell cycle and in response to DNA damage. This structural arrangement is vital for maintaining genomic stability and ensuring efficient DNA synthesis and repair, thereby preventing mutations that could lead to cancer. Upon genotoxic stress, p53R2 undergoes nuclear translocation, allowing for an immediate supply of dNTPs necessary for DNA repair processes mediated by the tumor suppressor protein p53. p53R2 (A-5) antibody facilitates advanced research into cell cycle regulation, DNA damage response, and molecular mechanisms underlying tumor suppression. p53R2 monoclonal antibody (A-5) serves as an indispensable tool for scientists investigating the structural and functional dynamics of ribonucleotide reductase in various biological contexts.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

p53R2 Antibody (A-5) References:

1. Impaired function of p53R2 in Rrm2b-null mice causes severe renal failure through attenuation of dNTP pools.  |  Kimura, T., et al. 2003. Nat Genet. 34: 440-5. PMID: 12858174
2. Kearns-Sayre syndrome caused by defective R1/p53R2 assembly.  |  Pitceathly, RD., et al. 2011. J Med Genet. 48: 610-7. PMID: 21378381
3. The roles of p53R2 in cancer progression based on the new function of mutant p53 and cytoplasmic p21.  |  Yousefi, B., et al. 2014. Life Sci. 99: 14-7. PMID: 24486301
4. Akt and p53R2, partners that dictate the progression and invasiveness of cancer.  |  Yousefi, B., et al. 2014. DNA Repair (Amst). 22: 24-9. PMID: 25086499
5. E2F1 regulates p53R2 gene expression in p53-deficient cells.  |  Qi, JJ., et al. 2015. Mol Cell Biochem. 399: 179-88. PMID: 25312903
6. Novel regulators and molecular mechanisms of p53R2 and its disease relevance.  |  Cho, EC. and Yen, Y. 2016. Biochimie. 123: 81-4. PMID: 26796884
7. p53R2 as a novel prognostic biomarker in nasopharyngeal carcinoma.  |  Chen, J., et al. 2017. BMC Cancer. 17: 846. PMID: 29237424
8. Phenotypic and Genotypic Heterogeneity of RRM2B Variants.  |  Finsterer, J. and Zarrouk-Mahjoub, S. 2018. Neuropediatrics. 49: 231-237. PMID: 29241262
9. Effect of siRNA-mediated silencing of p53R2 gene on sensitivity of T-ALL cellsto Daunorubicin.  |  Kiani Ghalesardi, O., et al. 2023. Gene. 880: 147622. PMID: 37419428
10. Targeting CK2-mediated phosphorylation of p53R2 sensitizes BRCA-proficient cancer cells to PARP inhibitors.  |  Wang, C., et al. 2023. Oncogene. 42: 2971-2984. PMID: 37620447

The preferred R2 antibody is R2 Antibody (A-5): sc-398294.